LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Anavex Life Sciences Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

9.11 0.77

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.88

Max

9.11

Pagrindiniai rodikliai

By Trading Economics

Pajamos

915K

-11M

Pelnas, tenkantis vienai akcijai

-0.132

Darbuotojai

42

EBITDA

106K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+213.53% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

34M

762M

Ankstesnė atidarymo kaina

8.34

Ankstesnė uždarymo kaina

9.11

Naujienos nuotaikos

By Acuity

50%

50%

156 / 381 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Anavex Life Sciences Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-20 18:52; UTC

Uždarbis

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

2025-06-20 16:15; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

2025-06-21 08:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-06-21 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-21 08:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-06-20 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-06-20 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-06-20 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-20 20:13; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

2025-06-20 20:11; UTC

Rinkos pokalbiai

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

2025-06-20 19:56; UTC

Rinkos pokalbiai

Crude Oil Slips to End Week -- Market Talk

2025-06-20 18:35; UTC

Rinkos pokalbiai

Warehouse Clubs Seen Growing Market Share -- Market Talk

2025-06-20 18:12; UTC

Rinkos pokalbiai

Gold Slides to Close Shortened Week -- Market Talk

2025-06-20 17:56; UTC

Rinkos pokalbiai

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

2025-06-20 17:50; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

2025-06-20 17:35; UTC

Įsigijimai, susijungimai, perėmimai

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

2025-06-20 17:30; UTC

Rinkos pokalbiai
Uždarbis

Adobe's AI Headwinds Seen Fading -- Market Talk

2025-06-20 17:03; UTC

Uždarbis

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

2025-06-20 16:50; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-06-20 16:50; UTC

Rinkos pokalbiai
Uždarbis

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

2025-06-20 16:44; UTC

Įsigijimai, susijungimai, perėmimai

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

2025-06-20 16:40; UTC

Rinkos pokalbiai
Uždarbis

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

2025-06-20 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-06-20 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-20 16:17; UTC

Įsigijimai, susijungimai, perėmimai

UniCredit: ULI and UVA Are Expected to Merge in 2026

2025-06-20 16:17; UTC

Įsigijimai, susijungimai, perėmimai

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

2025-06-20 16:05; UTC

Rinkos pokalbiai

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

2025-06-20 15:56; UTC

Rinkos pokalbiai
Uždarbis

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

2025-06-20 15:26; UTC

Rinkos pokalbiai

Natural Gas Slips After Streak of Higher Closes -- Market Talk

2025-06-20 15:25; UTC

Įsigijimai, susijungimai, perėmimai

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

Akcijų palyginimas

Kainos pokytis

Anavex Life Sciences Corp Prognozė

Kainos tikslas

By TipRanks

213.53% į viršų

12 mėnesių prognozė

Vidutinis 28.5 USD  213.53%

Aukščiausias 42 USD

Žemiausias 15 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Anavex Life Sciences Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.275 / 9.312Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

156 / 381 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.